Salem Investment Counselors Inc Amylyx Pharmaceuticals, Inc. Transaction History
Salem Investment Counselors Inc
- $3.07 Billion
- Q2 2025
A detailed history of Salem Investment Counselors Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Salem Investment Counselors Inc holds 55 shares of AMLX stock, worth $451. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55
Previous 55
-0.0%
Holding current value
$451
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding AMLX
# of Institutions
144Shares Held
76MCall Options Held
212KPut Options Held
40.6K-
Adage Capital Partners Gp, L.L.C. Boston, MA8.8MShares$72.2 Million0.1% of portfolio
-
Perceptive Advisors LLC New York, NY7.9MShares$64.9 Million2.22% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.94MShares$48.8 Million7.77% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.54MShares$37.2 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$36.9 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $481M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...